Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tetomilast.

Seamus O'Mahony1

  • 1Cork University Hospital, Wilton, Cork, Ireland. omahonys3@shb.ie

Idrugs : the Investigational Drugs Journal
|May 21, 2005
PubMed
Summary

Otsuka is developing tetomilast, a once-daily oral phosphodiesterase-4 inhibitor. This drug is being investigated for ulcerative colitis (phase III) and chronic obstructive pulmonary disease (phase II).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

After Gastroenterology: My Third Act.

Gastroenterology·2026
Same author

How Will the Future Judge Us?

Gastroenterology·2025
Same author

The Thing Itself: Medicine as Craft.

Gastroenterology·2025
Same author

Hacking Death in Dublin.

Gastroenterology·2024
Same author

Sir William Osler, the Two Cultures, and the Learned Profession.

Gastroenterology·2024
Same author

Why Gastroenterologists Should Be More Interested in Death.

Gastroenterology·2024

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Pulmonology

Background:

  • Ulcerative colitis and chronic obstructive pulmonary disease are significant inflammatory conditions.
  • Phosphodiesterase-4 (PDE4) inhibitors represent a therapeutic target for inflammatory diseases.

Purpose of the Study:

  • To evaluate the efficacy and safety of a novel, once-daily oral formulation of tetomilast.
  • To assess tetomilast's potential as a treatment for ulcerative colitis and chronic obstructive pulmonary disease.

Main Methods:

  • Phase III clinical trials for ulcerative colitis.
  • Phase II clinical trials for chronic obstructive pulmonary disease.
  • Pharmacokinetic and pharmacodynamic studies of oral tetomilast.

Main Results:

  • Data from ongoing trials will determine efficacy and safety profiles.
  • Tetomilast demonstrates potential for once-daily oral administration.

Conclusions:

  • Tetomilast is a promising phosphodiesterase-4 inhibitor for inflammatory conditions.
  • Further clinical development is warranted for ulcerative colitis and COPD treatment.

Related Experiment Videos